If you liked this article you might like

Seres Plunges on Microbiome Drug Fail, Execs Profit on Insider Sales
Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs
Celgene Second-Quarter Earnings Yield No Surprises, Small Guidance Bump
Biomarin Hemophilia Gene Therapy Advances on Strong Study Results